系统医学解析1q染色体扩增揭示多发性骨髓瘤中新型PBX1-FOXM1轴用于靶向治疗
本研究整合多发性骨髓瘤患者的多组学数据与遗传变量,参照三维染色质结构绘制1q染色体扩增相关临床风险图谱,鉴定出103个不良预后基因。其中转录因子PBX1因基因扩增和表观激活而异位表达,直接调控致癌通路和FOXM1依赖的转录程序。使用硫链丝菌素和新型PBX1小分子抑制剂T417药理学破坏PBX1-FOXM1轴,对1q扩增的骨髓瘤和实体瘤细胞具有选择性毒性。
要点
- 1q染色体扩增骨髓瘤中鉴定出103个不良预后基因,PBX1因基因扩增和表观激活而异位表达。
- PBX1结合重编程超级增强子,直接调控致癌通路和FOXM1依赖的转录程序。
- PBX1和FOXM1激活的增殖基因特征可预测多种癌症的不良预后。
核心结论
- 系统医学方法成功识别拷贝数变异驱动的致癌回路,将其与临床表型关联,并提出多发性骨髓瘤及其他癌症中新型拷贝数变异靶向治疗策略。
研究设计与样本
- 研究整合多发性骨髓瘤患者的多组学数据集与遗传变量,参照三维染色质结构进行分析。
主要发现
- 在1q染色体扩增的多发性骨髓瘤中鉴定出103个不良预后基因。
- 转录因子PBX1因基因扩增和其自身保留三维调控域的表观激活而异位表达。
- PBX1结合重编程的超级增强子,直接调控关键致癌通路和FOXM1依赖的转录程序。
- PBX1和FOXM1共同激活的增殖基因特征可预测多种癌症类型的不良预后。
- 使用现有药物硫链丝菌素和新型PBX1小分子抑制剂T417药理学破坏PBX1-FOXM1轴,对1q染色体扩增的骨髓瘤和实体瘤细胞具有选择性毒性。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Understanding the biological and clinical impact of copy number aberrations (CNAs) on the development of precision therapies in cancer remains an unmet challenge. Genetic amplification of chromosome 1q (chr1q-amp) is a major CNA conferring an adverse prognosis in several types of cancer, including in the blood cancer multiple myeloma (MM). Although several genes across chromosome 1 (chr1q) portend high-risk MM disease, the underpinning molecular etiology remains elusive. Here, with reference to the 3-dimensional (3D) chromatin structure, we integrate multi-omics data sets from patients with MM with genetic variables to obtain an associated clinical risk map across chr1q and to identify 103 adverse prognosis genes in chr1q-amp MM. Prominent among these genes, the transcription factor PBX1 is ectopically expressed by genetic amplification and epigenetic activation of its own preserved 3D regulatory domain. By binding to reprogrammed superenhancers, PBX1 directly regulates critical oncogenic pathways and a FOXM1-dependent transcriptional program. Together, PBX1 and FOXM1 activate a proliferative gene signature that predicts adverse prognosis across multiple types of cancer. Notably, pharmacological disruption of the PBX1-FOXM1 axis with existing agents (thiostrepton) and a novel PBX1 small molecule inhibitor (T417) is selectively toxic against chr1q-amp myeloma and solid tumor cells. Overall, our systems medicine approach successfully identifies CNA-driven oncogenic circuitries, links them to clinical phenotypes, and proposes novel CNA-targeted therapy strategies in MM and other types of cancer.
引用
- Trasanidis N, Katsarou A, Ponnusamy K, et al. Systems medicine dissection of chr1q-amp reveals a novel PBX1-FOXM1 axis for targeted therapy in multiple myeloma. Blood. 2022. PMID: 35015835. doi:10.1182/blood.2021014391
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。